Session Title: Beyond the kidneys: the importance of early intervention and managing cardiovascular risk in patients with CKD
Organized by: Boehringer Ingelheim GmbH
Session Description:
An emotional and compelling story for the audience to highlight the importance of addressing both cardiovascular and renal risk in our patients with CKD. The speakers will discuss international guideline recommendations for SGLT2 inhibitors (including empagliflozin) as a first-line therapy in people with CKD for cardiovascular and kidney protection. This session will highlight the importance of early and optimal intervention for patients with CKD regardless of their age
Learning Objectives:
1. Highlight the importance of early intervention for patients with CKD and the benefits of prompt disease management across all stages of CKD
2. Emphasise the urgent need for timely and effective intervention for frail and elderly patients with CKD in secondary care
3. Examine the elevated CV risk in a broad range of patients with CKD and discuss the range of evidence supporting the use of SGLT2 inhibitors for both kidney and CV benefits
| Time | Session |
|---|---|
|
17:00
17:05
|
Welcome and introduction
|
|
17:05
17:17
|
From evidence to practice: SGLT2 inhibitors as a foundational treatment for patients With CKD
|
|
17:17
17:32
|
Prompt action in CKD: increasing treatment benefits for your patients with CKD
|
|
17:32
17:45
|
The hidden burden: managing cardiovascular risk in patients with CKD
|
|
17:45
17:55
|
Audience Q&A
|
|
17:55
18:00
|
Summary and close
|